Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy.

Ali SM, Alpaugh RK, Downing SR, Stephens PJ, Yu JQ, Wu H, Buell JK, Miller VA, Lipson D, Palmer GA, Ross JS, Cristofanilli M.

J Clin Oncol. 2014 Sep 1;32(25):e88-91. doi: 10.1200/JCO.2013.49.0599. Epub 2014 Feb 10. No abstract available.

2.

Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies.

Ross JS, Wang K, Rand JV, Sheehan CE, Jennings TA, Al-Rohil RN, Otto GA, Curran JC, Palmer G, Downing SR, Yelensky R, Lipson D, Balasubramanian S, Garcia L, Mahoney K, Ali SM, Miller VA, Stephens PJ.

Am J Surg Pathol. 2014 Feb;38(2):235-8. doi: 10.1097/PAS.0000000000000102.

PMID:
24418857
3.

A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.

Ross JS, Wang K, Gay LM, Al-Rohil RN, Nazeer T, Sheehan CE, Jennings TA, Otto GA, Donahue A, He J, Palmer G, Ali S, Nahas M, Young G, Labrecque E, Frampton G, Erlich R, Curran JA, Brennan K, Downing SR, Yelensky R, Lipson D, Hawryluk M, Miller VA, Stephens PJ.

Clin Cancer Res. 2014 Jan 1;20(1):68-75. doi: 10.1158/1078-0432.CCR-13-1992. Epub 2013 Nov 5.

4.

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.

Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P, Sun J, Juhn F, Brennan K, Iwanik K, Maillet A, Buell J, White E, Zhao M, Balasubramanian S, Terzic S, Richards T, Banning V, Garcia L, Mahoney K, Zwirko Z, Donahue A, Beltran H, Mosquera JM, Rubin MA, Dogan S, Hedvat CV, Berger MF, Pusztai L, Lechner M, Boshoff C, Jarosz M, Vietz C, Parker A, Miller VA, Ross JS, Curran J, Cronin MT, Stephens PJ, Lipson D, Yelensky R.

Nat Biotechnol. 2013 Nov;31(11):1023-31. doi: 10.1038/nbt.2696. Epub 2013 Oct 20.

5.

Novel methylation biomarker panel for the early detection of pancreatic cancer.

Yi JM, Guzzetta AA, Bailey VJ, Downing SR, Van Neste L, Chiappinelli KB, Keeley BP, Stark A, Herrera A, Wolfgang C, Pappou EP, Iacobuzio-Donahue CA, Goggins MG, Herman JG, Wang TH, Baylin SB, Ahuja N.

Clin Cancer Res. 2013 Dec 1;19(23):6544-6555. doi: 10.1158/1078-0432.CCR-12-3224. Epub 2013 Oct 2.

6.

Is laparoscopy a risk factor for bile duct injury during cholecystectomy?

Fullum TM, Downing SR, Ortega G, Chang DC, Oyetunji TA, Van Kirk K, Tran DD, Woods I, Cornwell EE, Turner PL.

JSLS. 2013 Jul-Sep;17(3):365-70. doi: 10.4293/108680813X13654754535638.

7.

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.

Ross JS, Wang K, Al-Rohil RN, Nazeer T, Sheehan CE, Otto GA, He J, Palmer G, Yelensky R, Lipson D, Ali S, Balasubramanian S, Curran JA, Garcia L, Mahoney K, Downing SR, Hawryluk M, Miller VA, Stephens PJ.

Mod Pathol. 2014 Feb;27(2):271-80. doi: 10.1038/modpathol.2013.135. Epub 2013 Jul 26.

8.

Open versus laparoscopic hiatal hernia repair.

Fullum TM, Oyetunji TA, Ortega G, Tran DD, Woods IM, Obayomi-Davies O, Pessu O, Downing SR, Cornwell EE.

JSLS. 2013 Jan-Mar;17(1):23-9. doi: 10.4293/108680812X13517013316951.

9.

Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.

Ross JS, Wang K, Sheehan CE, Boguniewicz AB, Otto G, Downing SR, Sun J, He J, Curran JA, Ali S, Yelensky R, Lipson D, Palmer G, Miller VA, Stephens PJ.

Clin Cancer Res. 2013 May 15;19(10):2668-76. doi: 10.1158/1078-0432.CCR-13-0295. Epub 2013 Apr 10.

10.

Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics.

Mayer EL, Isakoff SJ, Klement G, Downing SR, Chen WY, Hannagan K, Gelman R, Winer EP, Burstein HJ.

Breast Cancer Res Treat. 2012 Nov;136(1):169-78. doi: 10.1007/s10549-012-2256-5. Epub 2012 Sep 23.

11.

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.

Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM, Stephens PJ, Mosquera JM, Cronin MT, Rubin MA.

Eur Urol. 2013 May;63(5):920-6. doi: 10.1016/j.eururo.2012.08.053. Epub 2012 Sep 5.

12.

Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer.

Straume O, Shimamura T, Lampa MJ, Carretero J, Øyan AM, Jia D, Borgman CL, Soucheray M, Downing SR, Short SM, Kang SY, Wang S, Chen L, Collett K, Bachmann I, Wong KK, Shapiro GI, Kalland KH, Folkman J, Watnick RS, Akslen LA, Naumov GN.

Proc Natl Acad Sci U S A. 2012 May 29;109(22):8699-704. doi: 10.1073/pnas.1017909109. Epub 2012 May 15.

13.

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.

Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, Curran JA, Balasubramanian S, Bloom T, Brennan KW, Donahue A, Downing SR, Frampton GM, Garcia L, Juhn F, Mitchell KC, White E, White J, Zwirko Z, Peretz T, Nechushtan H, Soussan-Gutman L, Kim J, Sasaki H, Kim HR, Park SI, Ercan D, Sheehan CE, Ross JS, Cronin MT, Jänne PA, Stephens PJ.

Nat Med. 2012 Feb 12;18(3):382-4. doi: 10.1038/nm.2673.

14.

Isolation and proteomic analysis of platelets by SELDI-TOF MS.

Downing SR, Klement GL.

Methods Mol Biol. 2012;818:153-70. doi: 10.1007/978-1-61779-418-6_12.

15.

Early-stage gallbladder cancer in the Surveillance, Epidemiology, and End Results database: effect of extended surgical resection.

Downing SR, Cadogan KA, Ortega G, Oyetunji TA, Siram SM, Chang DC, Ahuja N, Leffall LD Jr, Frederick WA.

Arch Surg. 2011 Jun;146(6):734-8. doi: 10.1001/archsurg.2011.128.

PMID:
21690451
16.

Treatment outcomes of injured children at adult level 1 trauma centers: are there benefits from added specialized care?

Oyetunji TA, Haider AH, Downing SR, Bolorunduro OB, Efron DT, Haut ER, Chang DC, Cornwell EE 3rd, Abdullah F, Siram SM.

Am J Surg. 2011 Apr;201(4):445-9. doi: 10.1016/j.amjsurg.2010.10.006.

PMID:
21421097
17.

Genomic and epigenomic integration identifies a prognostic signature in colon cancer.

Yi JM, Dhir M, Van Neste L, Downing SR, Jeschke J, Glöckner SC, de Freitas Calmon M, Hooker CM, Funes JM, Boshoff C, Smits KM, van Engeland M, Weijenberg MP, Iacobuzio-Donahue CA, Herman JG, Schuebel KE, Baylin SB, Ahuja N.

Clin Cancer Res. 2011 Mar 15;17(6):1535-45. doi: 10.1158/1078-0432.CCR-10-2509. Epub 2011 Jan 28.

18.

The impact of insurance status on actuarial survival in hospitalized trauma patients: when do they die?

Downing SR, Oyetunji TA, Greene WR, Jenifer J, Rogers SO Jr, Haider AH, Cornwell EE 3rd, Chang DC.

J Trauma. 2011 Jan;70(1):130-4; discussion 134-5. doi: 10.1097/TA.0b013e3182032b34. Erratum in: J Trauma. 2011 Feb;70(2):525. Cornwell, Edward E 3rd [added].

PMID:
21217490
19.

Asian race/ethnicity as a risk factor for bile duct injury during cholecystectomy.

Downing SR, Datoo G, Oyetunji TA, Fullum T, Chang DC, Ahuja N.

Arch Surg. 2010 Aug;145(8):785-7. doi: 10.1001/archsurg.2010.131.

20.

The number of lymph nodes examined debate in colon cancer: how much is enough?

Downing SR, Cadogan KA, Ortega G, Jaji Z, Bolorunduro OB, Oyetunji TA, Chang DC, Ford DH, Frederick WA.

J Surg Res. 2010 Oct;163(2):264-9. doi: 10.1016/j.jss.2010.03.017. Epub 2010 Apr 1.

PMID:
20638686
21.

Surgical treatment for women with breast cancer: do randomized clinical trials represent current medical practices?

Frederick WA, Ames S, Downing SR, Oyetunji TA, Chang DC, Leffall LD Jr.

Am Surg. 2010 Jun;76(6):630-6.

PMID:
20583521
22.

Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: application to mass spec data.

Park Y, Downing SR, Kim D, Hahn WC, Li C, Kantoff PW, Wei LJ.

Bioinformatics. 2007 Jun 15;23(12):1451-8. Epub 2007 Apr 25.

PMID:
17459967
23.

Mutations in ribonuclease L gene do not occur at a greater frequency in patients with familial prostate cancer compared with patients with sporadic prostate cancer.

Downing SR, Hennessy KT, Abe M, Manola J, George DJ, Kantoff PW.

Clin Prostate Cancer. 2003 Dec;2(3):177-80.

PMID:
15040862
24.

Alterations of p53 are common in early stage prostate cancer.

Downing SR, Russell PJ, Jackson P.

Can J Urol. 2003 Aug;10(4):1924-33. Review.

PMID:
14503938
25.
26.

Evidence for post-transcriptional down-regulation of the apoptosis-related gene bcl-2 in human colorectal cancer.

Berney CR, Downing SR, Yang JL, Russell PJ, Crowe PJ.

J Pathol. 2000 May;191(1):15-20.

PMID:
10767713
27.

Elevated expression of FGF-2 does not cause prostate cancer progression in LNCaP cells.

Russell PJ, Bennett S, Joshua A, Yu Y, Downing SR, Hill MA, Kingsley EA, Mason RS, Berry J.

Prostate. 1999 Jun 15;40(1):1-13.

PMID:
10344718
28.

Delayed involution of the mammary epithelium in BALB/c-p53null mice.

Jerry DJ, Kuperwasser C, Downing SR, Pinkas J, He C, Dickinson E, Marconi S, Naber SP.

Oncogene. 1998 Nov 5;17(18):2305-12.

29.

The patient who has peritoneal dialysis. Care during the exchange.

Downing SR.

Am J Nurs. 1966 Jul;66(7):1572-7. No abstract available.

PMID:
5177343

Supplemental Content

Loading ...
Support Center